OK.
reading about FDA Breakthrough Device Exemption has been interesting.
I’m starting to wonder if comments here about pivotal trials might not have accounted for the radical nature of this status.
It’s possible that if FDA likes what OSL is showing, might it not need to undertake classical pivotal RCT trials.
It may allow it into the market with staged approval using post marketing surveillance.
Marketing approval in 18 months is not impossible.
Happy to be contradicted, but my research suggests it’s possible.
- Forums
- ASX - By Stock
- OSL
- Ann: Oncosil breakthrough device receives CE Marking approval
Ann: Oncosil breakthrough device receives CE Marking approval, page-165
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OSL (ASX) to my watchlist
|
|||||
Last
0.6¢ |
Change
-0.001(7.69%) |
Mkt cap ! $20.38M |
Open | High | Low | Value | Volume |
0.7¢ | 0.7¢ | 0.6¢ | $33.26K | 4.842M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 3229003 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 20409639 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 3229003 | 0.006 |
25 | 18383399 | 0.005 |
33 | 24234949 | 0.004 |
9 | 11539965 | 0.003 |
6 | 5457516 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 20409639 | 24 |
0.008 | 14287076 | 13 |
0.009 | 14522573 | 8 |
0.010 | 7983000 | 7 |
0.012 | 10910 | 1 |
Last trade - 13.45pm 11/07/2024 (20 minute delay) ? |
Featured News
CXO
Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
OSL (ASX) Chart |